PT - JOURNAL ARTICLE AU - Ha My T. Vy AU - Sergio Dellepiane AU - Kumardeep Chaudhary AU - Alexander Blair AU - Benjamin S Glicksberg AU - Steven G Coca AU - Lili Chan AU - John Cijiang He AU - Ron Do AU - Girish N Nadkarni TI - Genome-wide polygenic risk score method for diabetic kidney disease in patients with type 2 diabetes AID - 10.1101/2021.07.09.21260114 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.09.21260114 4099 - http://medrxiv.org/content/early/2021/07/10/2021.07.09.21260114.short 4100 - http://medrxiv.org/content/early/2021/07/10/2021.07.09.21260114.full AB - Diabetic kidney disease (DKD) is considered partially hereditary, but the genetic factors underlying disease remain largely unknown. A key barrier to our understanding stems from its heterogeneity, and likely polygenic etiology. Proteinuric and non-proteinuric DKD are two sub-classes of DKD, defined by high urinary albumin-to-creatinine ratio (UACR) and low creatinine estimated glomerular filtration rate (eGFR). Prior genome-wide association studies (GWAS) have identified multiple loci associated with eGFR and UACR. We aimed to combine summary statistics from previous GWAS’ for eGFR and UACR in one prediction model and associate it with DKD prevalence. We then tested this using genetic data from 18,841 individuals diagnosed with type 2 diabetes in UK Biobank. We computed two genome-wide polygenic risk scores (GPS) aggregating effects of common variants associated with the two measurements, eGFR and UACR. We show that including both GPS’ in a single model confers significant improvement in comparison with the single GPS model generated from GWAS summary statistics for DKD. We also find in replication analysis in 5,389 individuals in the multi-ethnic BioMe Biobank, that although the combined model had consistent direction of association, the lowest performance was in individuals with recent African ancestry. In summary, we show that joint modeling of polygenic associations of eGFR and UACR is more significantly associated with DKD than individual modeling as well as a GPS comprised of only DKD summary statistics and may be used to gain insights into biology and progression. However, efforts should be made to develop and validate polygenic approaches in diverse populations.Competing Interest StatementGNN, JCH and SGC receive financial compensation as consultants and advisory board members for Renalytix, and own equity in Renalytix. In the past 3 years, SGC has also received consulting fees from CHF Solutions, Takeda Pharmaceuticals, Relypsa, Bayer, Goldfinch Bio, Boehringer-Ingelheim, and inRegen. In the past 3 years GNN has also received consulting fees from AstraZeneca, Reata, GLG Consulting, BioVie, Variant Bio, and grant support from Goldfinch Bio and Renalytix. GNN is also a scientific cofounder and equity holder for Pensieve Health. LC receives financial compensation as a consultant for Vifor Pharma, INC and honorarium from Fresenius Medical Care. Ron Do reported receiving grants from AstraZeneca, grants and nonfinancial support from Goldfinch Bio, being a scientific cofounder and equity holder for Pensieve Health and being a consultant for Variant Bio.Funding StatementResearch reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. This study has been conducted using the UK Biobank Resource under Application Number 16218. Iain S. Forrest was supported by T32GM007280, the Medical Scientist Training Program Training Grant from the National Institute of General Medical Sciences of the National Institutes of Health. Ron Do is supported by R35GM124836 from the National Institute of General Medical Sciences of the National Institutes of Health, and R01HL155915 and R01HL139865 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Girish Nadkarni is supported by R01DK127139 from the National Institute of Diabetes and Digestive and Kidney Disease and by R01HL155915 from the National Heart, Lung, and Blood Institute of the National Institutes of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been conducted using the UK Biobank Resource under Application Number 16218. UK Biobank has received ethics approval from the North West Multi-centre Research Ethics Committee, the National Information Governance Board for Health & Social Care, and the Community Health Index Advisory Group. BioMe BioBank data set was approved under IRB-19-02369 by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.